Revolution Medicines delivered updated evidence for daraxonrasib, its oral multi-selective inhibitor targeting RAS, at AACR, adding first-line and combination readouts in metastatic pancreatic ductal adenocarcinoma (PDAC). The new dataset follows previously reported Phase 3 results in previously treated patients that showed a survival benefit versus chemotherapy. In the first-line studies presented, daraxonrasib was evaluated as monotherapy and in combination with chemotherapy across cohorts with different RAS mutation statuses. Monotherapy data reported tumor shrinkage or disappearance in 47% of patients and disease progression–free survival markers including 71% alive without progression at six months. In the combination arm, those figures were 58% and 84%, respectively. The presentation keeps pressure on the Phase 3 RASolute 303 program, which is already enrolling previously untreated patients irrespective of tumor RAS genotype. Wall Street interest also intensified after the earlier Phase 3 win and the company’s associated financing activity, though competing narratives on takeover speculation remain mixed. Overall, the AACR update positions daraxonrasib as a potential shift in the standard of care for a heavily RAS-driven, chemotherapy-resistant cancer population where durable outcomes remain scarce.